Turnstone Biologics CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Point72 Asset Management and its affiliates, including Steven A. Cohen, have reported a 0% beneficial ownership stake in Turnstone Biologics Corp. as of September 30, 2025.
SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 4.9% Passive Stake in Turnstone Biologics Corp.
FMR LLC and its affiliate Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.9% in Turnstone Biologics Corp.'s common stock as of March 31, 2025.